NeurOn Pharmaceuticals

NeurOn Pharmaceuticals was a clinical-stage biopharmaceutical company based in Basel, Switzerland, that specialized in the development of therapies for neurodegenerative diseases. The company's lead candidate, N-001, was a proprietary formulation of a known therapeutic agent designed to provide neuroprotection in patients with Amyotrophic Lateral Sclerosis (ALS). NeurOn successfully advanced N-001 into Phase 2 clinical trials to evaluate its safety and efficacy. Despite receiving significant venture capital backing from firms such as Index Ventures and TVM Capital, the company has since become inactive. Its business model focused on the reformulation of existing compounds to address unmet needs in the central nervous system space.